Integra LifeSciences Holdings Corporation
Financials
Valuation Metrics
Integra LifeSciences Holdings Corporation's Market Cap is $1.39B. At end of 2025 it was $953M. Ranked #2291 of 3,112 in US market (top 74%), #916 of 1,445 on NASDAQ (top 63%), #141 of 206 in Health Care Equipment & Services (top 68%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.39B | US#2,291/3,112 Sec#141/206 |
| Revenue | $1.65B | US#1,600/3,112 Sec#97/206 |
| Net Income | $-7M | US—/3,112 Sec—/206 |
| Total Assets | $3.59B | US#1,664/3,112 Sec#78/206 |
| Net Assets | $1.05B | US#1,747/3,112 Sec#92/206 |
| Employees | 4,427 | US#886/3,112 Sec#75/206 |
| Value | ||
| P/B | 1.32x | US#655/3,112 Sec#38/206 |
| P/S | 0.84x | US#545/3,112 Sec#42/206 |
| EV/EBITDA | 15.27x | US#1,515/3,112 Sec#62/206 |
| FCF Yield | 2.79% | US#1,800/3,112 Sec#108/206 |
| Profitability | ||
| ROE | -0.69% | US#2,177/3,112 Sec#114/206 |
| ROA | -0.20% | US#2,231/3,112 Sec#117/206 |
| Op. Margin | 39.81% | US#233/3,112 Sec#4/206 |
| Revenue Growth | 0.76% | US#2,170/3,112 Sec#167/206 |
| Financial Health | ||
| Debt Ratio | 241.29% | US#1,954/3,112 Sec#168/206 |
| Total Debt | $2.04B | US#1,121/3,112 Sec#58/206 |
| FCF | $39M | US#2,017/3,112 Sec#124/206 |
| Cash | $214M | US#1,674/3,112 Sec#96/206 |
| Current Ratio | 3.40x | US#690/3,112 Sec#71/206 |
| Net Debt/EBITDA | 8.66x | US#2,334/3,112 Sec#133/206 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,112 Sec—/206 |
| Payout Ratio | 0.00% | US—/3,112 Sec—/206 |
| Performance | ||
| 1Y Return | 42.36% | US#892/3,112 Sec#62/206 |
| 1M Return | -0.94% | US#1,779/3,112 Sec#120/206 |
| From 52W High | -12.74% | US#1,247/3,112 Sec#91/206 |
| 1Y MDD | -44.79% | US#2,199/3,112 Sec#129/206 |
| Trading | ||
| Volume | 550,771 shares | US#1,313/3,112 Sec#84/206 |
| Trading Value | $10M | US#1,911/3,112 Sec#131/206 |
| Per Share | ||
| EPS | $-6.74 | US—/3,112 Sec—/206 |
| BPS | $13.40 | US#1,571/3,112 Sec#89/206 |
Company Info
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.